Literature DB >> 34725197

Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis.

Keeley M Fairbrass1,2, Jessica Lovatt1, Brigida Barberio3, Yuhong Yuan4, David J Gracie1,2, Alexander C Ford5,2.   

Abstract

OBJECTIVE: The role of the brain-gut axis is of increasing interest in IBD, as the link between common mental disorders and GI inflammation may be bidirectional. We performed a systematic review examining these issues.
DESIGN: We searched EMBASE Classic and EMBASE, Medline, and APA PsychInfo (to 11 July 2021) for longitudinal follow-up studies examining effect of symptoms of anxiety or depression on subsequent adverse outcomes in IBD, or effect of active IBD on subsequent development of symptoms of anxiety or depression. We pooled relative risks (RRs) and HRs with 95% CIs for adverse outcomes (flare, escalation of therapy, hospitalisation, emergency department attendance, surgery or a composite of any of these) according to presence of symptoms of anxiety or depression at baseline, or RRs and HRs with 95% CIs for new onset of symptoms of anxiety or depression according to presence of active IBD at baseline.
RESULTS: We included 12 separate studies, recruiting 9192 patients. All 12 studies examined brain-to-gut effects. Anxiety at baseline was associated with significantly higher risks of escalation of therapy (RR=1.68; 95% CI 1.18 to 2.40), hospitalisation (RR=1.72; 95% CI 1.01 to 2.95), emergency department attendance (RR=1.30; 95% CI 1.21 to 1.39), or a composite of any adverse outcome. Depression at baseline was associated with higher risks of flare (RR=1.60; 95% CI 1.21 to 2.12), escalation of therapy (RR=1.41; 95% CI 1.08 to 1.84), hospitalisation (RR=1.35; 95% CI 1.17 to 1.57), emergency department attendance (RR=1.38; 95% CI 1.22 to 1.56), surgery (RR=1.63; 95% CI 1.19 to 2.22) or a composite of any of these. Three studies examined gut-to-brain effects. Active disease at baseline was associated with future development of anxiety or depression (RR=2.24; 95% CI 1.25 to 4.01 and RR=1.49; 95% CI 1.11 to 1.98, respectively).
CONCLUSION: Bidirectional effects of the brain-gut axis are present in IBD and may influence both the natural history of the disease and psychological health. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain/gut interaction; crohn's disease; inflammatory bowel disease; psychology; ulcerative colitis

Mesh:

Year:  2021        PMID: 34725197     DOI: 10.1136/gutjnl-2021-325985

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   31.793


  4 in total

Review 1.  Gut microbiome-mediated regulation of neuroinflammation.

Authors:  John W Bostick; Aubrey M Schonhoff; Sarkis K Mazmanian
Journal:  Curr Opin Immunol       Date:  2022-04-21       Impact factor: 7.268

2.  Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial.

Authors:  Chang Liang; Pingrun Chen; Yu Tang; Chuheng Zhang; Na Lei; Ying Luo; Shihao Duan; Yan Zhang
Journal:  Front Psychiatry       Date:  2022-05-19       Impact factor: 5.435

3.  Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease.

Authors:  Anna Nemirovsky; Karny Ilan; Livnat Lerner; Liel Cohen-Lavi; Doron Schwartz; Ganit Goren; Ruslan Sergienko; Dan Greenberg; Vered Slonim-Nevo; Orly Sarid; Michael Friger; Shirley Regev; Shmuel Odes; Tomer Hertz; Alon Monsonego
Journal:  Brain Behav Immun Health       Date:  2021-12-23

Review 4.  The Gut-Immune-Brain Axis: An Important Route for Neuropsychiatric Morbidity in Inflammatory Bowel Disease.

Authors:  Rebecca Katharina Masanetz; Jürgen Winkler; Beate Winner; Claudia Günther; Patrick Süß
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.